Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanadaBis CapitalTSXV:CANB Equity-to-Asset is 0.27 as of Oct. 2025, which is 16% below its 10-year median of 0.32. The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, CanadaBis Capital ranks worse than 82.13% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CanadaBis Capital's Total Stockholders Equity for the quarter that ended in Oct. 2025 was C$6.49 Mil. CanadaBis Capital's Total Assets for the quarter that ended in Oct. 2025 was C$24.43 Mil.
Therefore, CanadaBis Capital's Equity to Asset Ratio for the quarter that ended in Oct. 2025 was 0.27.
The historical rank and industry rank for CanadaBis Capital's Equity-to-Asset or its related term are showing as below:
TSXV:CANB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11 Med: 0.32 Max: 1
Current: 0.32
During the past 9 years, the highest Equity to Asset Ratio of CanadaBis Capital was 1.00. The lowest was 0.11. And the median was 0.32.
TSXV:CANB's Equity-to-Asset is ranked worse than 82.13% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs TSXV:CANB: 0.32
CanadaBis Capital (TSXV:CANB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CanadaBis Capital Equity-to-Asset Related Terms
CanadaBis Capital Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs STEK, GCAN, GRPS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CanadaBis Capital's Equity to Asset Ratio for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (TSXV:CANB) has a Equity-to-Asset of 0.27 as of Oct. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CanadaBis Capital and its competitors. This is 16% below median its historical median of 0.32. Over the past decade, CanadaBis Capital's Equity-to-Asset has ranged from 0.11 to 1.00. According to the industry distribution chart, CanadaBis Capital ranks #827 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 82.1%.
Is CanadaBis Capital's Equity-to-Asset too high?
CanadaBis Capital's current Equity-to-Asset of 0.27 is 16% below median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 1.00. The Drug Manufacturers industry median Equity-to-Asset is 0.60. CanadaBis Capital's value of 0.27 is 55% below this industry median. Based on the distribution chart, CanadaBis Capital ranks #827 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CanadaBis Capital's Equity-to-Asset compare to STEK and GCAN?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #827 out of 1007 companies for Equity-to-Asset. This places CanadaBis Capital in the lower half of its industry. The industry median Equity-to-Asset is 0.60. CanadaBis Capital's value of 0.27 is 55% below this benchmark. Historically, CanadaBis Capital's own Equity-to-Asset has ranged from 0.11 to 1.00 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 0.60, CanadaBis Capital has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current Equity-to-Asset of 0.27 is 55% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current Equity-to-Asset is 0.27, which is 16% below median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Equity-to-Asset of 0.27. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Equity-to-Asset is 0.27, which is 16% below median its 10-year median of 0.32 and 55% below the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Equity-to-Asset is 0.27 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 
